Results from the phase 3 SELECT-GCA study revealed that the JAK inhibitor upadacitinib showed significant and sustained remission in people with giant cell arteritis (GCA). The study included 210 individuals treated with upadacitinib and 105 treated with placebo. Upadacitinib resulted in sustained remission in 46% of patients compared to 29% in the placebo group. Secondary endpoints also showed positive results for upadacitinib. The study highlighted the need for new treatment options for GCA, as current options often do not lead to a cure. Upadacitinib showed promise in effectively treating GCA and had a good safety profile in the study.
Source link
Upadacitinib Improves Giant Cell Arteritis in Phase 3 Trial
